hypertension

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure,…

1 week ago

Serenity Medical Announces Clinical Publication of First Prospective Multicenter Trial of the River Stent, a Novel Venous Sinus Stent for Treating Idiopathic Intracranial Hypertension (IIH)

HARRISON, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company dedicated to the treatment…

4 weeks ago